[go: up one dir, main page]

CO5590913A2 - Terapia de combinacion antivirica - Google Patents

Terapia de combinacion antivirica

Info

Publication number
CO5590913A2
CO5590913A2 CO04064572A CO04064572A CO5590913A2 CO 5590913 A2 CO5590913 A2 CO 5590913A2 CO 04064572 A CO04064572 A CO 04064572A CO 04064572 A CO04064572 A CO 04064572A CO 5590913 A2 CO5590913 A2 CO 5590913A2
Authority
CO
Colombia
Prior art keywords
cox
inhibitor
antivirical
effective amount
combination therapy
Prior art date
Application number
CO04064572A
Other languages
English (en)
Inventor
Teck Chong Kong
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of CO5590913A2 publication Critical patent/CO5590913A2/es

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L21/00—Processes or apparatus adapted for the manufacture or treatment of semiconductor or solid state devices or of parts thereof
    • H01L21/02—Manufacture or treatment of semiconductor devices or of parts thereof
    • H01L21/027—Making masks on semiconductor bodies for further photolithographic processing not provided for in group H01L21/18 or H01L21/34

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Manufacturing & Machinery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Rheumatology (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Computer Hardware Design (AREA)
  • Microelectronics & Electronic Packaging (AREA)
  • Power Engineering (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

1.- Un método para tratar el PV, que comprende administrar a un mamífero que necesite un tratamiento del PV, una cantidad terapéuticamente eficaz de un inhibidor de COX-2 o su sal farmacéuticamente aceptable, y una cantidad terapéuticamente eficaz de un agente antivírico o su sal farmacéuticamente aceptable.2.- El método de la reivindicación 1, en el que la cantidad eficaz del inhibidor de COX-2 y el agente antivírico se administra al mamífero por vía tópica.3.- El método de la reivindicación 1, en el que el inhibidor de COX-2 y el agente antivírico se incluyen como componentes de una composición farmacéutica, en la que la composición farmacéutica comprende además un potenciador de la permeación.
CO04064572A 2002-01-10 2004-07-08 Terapia de combinacion antivirica CO5590913A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34755002P 2002-01-10 2002-01-10

Publications (1)

Publication Number Publication Date
CO5590913A2 true CO5590913A2 (es) 2005-12-30

Family

ID=23364195

Family Applications (1)

Application Number Title Priority Date Filing Date
CO04064572A CO5590913A2 (es) 2002-01-10 2004-07-08 Terapia de combinacion antivirica

Country Status (16)

Country Link
US (1) US20030211163A1 (es)
EP (1) EP1463500A1 (es)
JP (1) JP2005519061A (es)
KR (1) KR20040072720A (es)
CN (1) CN1697654A (es)
AU (1) AU2003201811A1 (es)
BR (1) BR0306820A (es)
CA (1) CA2472459A1 (es)
CO (1) CO5590913A2 (es)
IL (1) IL162726A0 (es)
MX (1) MXPA04006572A (es)
NO (1) NO20043313L (es)
PL (1) PL371252A1 (es)
RU (1) RU2004121147A (es)
WO (1) WO2003059347A1 (es)
ZA (1) ZA200404881B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7740868B2 (en) 1999-08-25 2010-06-22 Allergan, Inc. Activatable clostridial toxins
CA2380457A1 (en) 1999-08-25 2001-03-01 Allergan Sales, Inc. Activatable recombinant neurotoxins
AU2003243215A1 (en) * 2002-05-30 2003-12-19 Pharmacia And Upjohn Company Treatment for human papillomavirus
EP1572186A2 (en) * 2002-12-19 2005-09-14 Pharmacia Corporation Methods and compositions for the treatment of herpes virus infections using cyclooxygenase-2 selective inhibitors or cyclooxygenase-2 inhibitors in combination with antiviral agents
EP1689361A4 (en) 2003-12-02 2009-06-17 3M Innovative Properties Co THERAPEUTIC COMBINATIONS AND PROCESSES WITH IRM COMPOUNDS
US20100009928A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
US8080560B2 (en) * 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
AR054336A1 (es) * 2005-03-30 2007-06-20 Astion Dev As Tratamiento de enfermedades dermatologicas y del prurito
CN101588805A (zh) 2005-05-18 2009-11-25 Alt解决方案公司 为预防和治疗癌症对癌细胞中端粒长度的药理学调节
KR100644968B1 (ko) * 2005-10-28 2006-11-14 한국과학기술연구원 생체적합성 실리콘 나노입자의 제조 방법
DK2081562T3 (en) 2006-09-20 2016-05-30 Univ Texas Method of administering volatile anesthetics for regional anesthesia and / or pain relief
ITRM20080027A1 (it) * 2008-01-18 2009-07-19 Maria Balestrieri Uso di aciclovir per il trattamento delle condilomatosi.
EP2244737B1 (en) 2008-01-22 2019-04-10 The Board of Regents of The University of Texas System Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief
CA2721586A1 (en) * 2008-04-15 2009-10-22 Mallinckrodt Inc. Compositions containing antiviral compounds and methods of using the same
IL192335A0 (en) * 2008-06-19 2011-08-01 Avivi Easy Life Ltd Antiviral compounds
US20110218241A1 (en) * 2010-03-06 2011-09-08 Cacao Bio-Technologies, Llc Antiviral epicatechins, epicatechin oligomers, or thiolated epicatechins from theobroma cacao for treatment of genital warts
JP2012020991A (ja) * 2010-06-16 2012-02-02 Takasago Internatl Corp 経皮吸収促進剤、及びこれを含有する皮膚外用製剤
ES2769924T3 (es) 2012-02-06 2020-06-29 Innovative Med Concepts Llc Compuesto antiviral y terapia de combinación de inhibidores de la COX-2 para la fibromialgia
TWI646091B (zh) * 2012-12-28 2019-01-01 日商衛斯克慧特股份有限公司 鹽類及晶形
WO2016036588A1 (en) * 2014-09-03 2016-03-10 Merck Sharp & Dohme Corp. Pharmaceutical suspensions containing etoricoxib
CN105906496A (zh) * 2016-05-16 2016-08-31 苏州毕诺佳医药技术有限公司 一种阿昔洛韦的药物组合物及其医药用途
CN114423423B (zh) * 2020-12-28 2022-09-06 中以海德人工智能药物研发股份有限公司 一种用于治疗或预防病毒性肝炎的药物组合物及其应用
WO2022245950A1 (en) * 2021-05-19 2022-11-24 University Of Miami Treatment of infections in and around the eye

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6114314A (en) * 1992-02-21 2000-09-05 Hyal Pharmaceutical Corp. Formulations containing hyaluronic acid
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
US6180651B1 (en) * 1996-04-04 2001-01-30 Bristol-Myers Squibb Diarylmethylidenefuran derivatives, processes for their preparation and their uses in therapeutics
EP1288206B1 (en) * 1996-04-12 2008-09-17 G.D. Searle LLC Substituted benzenesulfonamide derivatives as prodrugs of COX-2 inhibitors
GB9615867D0 (en) * 1996-07-03 1996-09-11 Merck & Co Inc Process of preparing phenyl heterocycles useful as cox-2 inhibitors
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
WO1999030721A1 (en) * 1997-12-17 1999-06-24 Cornell Research Foundation, Inc. Cyclooxygenase-2 inhibition
IL146130A0 (en) * 1999-05-14 2002-07-25 Univ California Anti-inflammatory therapy for inflammatory mideated infection
US20030004142A1 (en) * 2001-04-18 2003-01-02 Prior Christopher P. Use of NSAIDs for prevention and treatment of cellular abnormalities of the lung or bronchial pathway
US20030004143A1 (en) * 2001-04-18 2003-01-02 Prior Christopher P. Use of NSAIDs for prevention and treatment of cellular abnormalities of the female reproductive tract

Also Published As

Publication number Publication date
BR0306820A (pt) 2004-12-07
EP1463500A1 (en) 2004-10-06
WO2003059347A1 (en) 2003-07-24
NO20043313L (no) 2004-10-08
MXPA04006572A (es) 2005-11-04
US20030211163A1 (en) 2003-11-13
PL371252A1 (en) 2005-06-13
AU2003201811A1 (en) 2003-07-30
ZA200404881B (en) 2005-08-31
CA2472459A1 (en) 2003-07-24
RU2004121147A (ru) 2005-04-10
CN1697654A (zh) 2005-11-16
IL162726A0 (en) 2005-11-20
KR20040072720A (ko) 2004-08-18
JP2005519061A (ja) 2005-06-30

Similar Documents

Publication Publication Date Title
CO5590913A2 (es) Terapia de combinacion antivirica
BR0111800A (pt) Combinações de inibidores de depeptidil peptidase iv e outros agentes antidiabéticos para o tratamento de diabete mellitus
AR070047A1 (es) Tratamientos terapeuticos contra el cancer. composicion que comprende un inhibidor de hedgehog.
CO5670356A2 (es) Programa de dosificaicon para un nuevo agente anticanceroso
CO5640076A2 (es) Composicion farmaceutica que comprende un inhibidor de ibat para el tratamiento o profilaxis del estreñimiento
UY26635A1 (es) Métodos sinérgicos y composiciones para el tratamiento del cáncer
CO2022013777A2 (es) Uso de agentes para el tratamiento de condiciones respiratorias
AR072442A1 (es) Metodo para la terapia del cancer, uso, kit
CO6160236A2 (es) Inhibidor de quinasa
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
AR029825A1 (es) Una composicion farmaceuticamente aceptable que comprende carvedilol o una sal del mismo farmaceuticamente aceptable, un procedimiento para la produccion de dicha composicion y utilizacion de la misma
AR049955A1 (es) Composiciones y metodos para el tratamiento de trastornos metabolicos
ECSP10010589A (es) Farmaco contra el cancer de higado
CO6150136A2 (es) Combinacion de adapaleno y peroxido de benzoilo para tratar lesiones de acne
IL300151A (en) Combinations for the treatment of cancer
AR040248A1 (es) Farmaco para el tratamiento de la vejiga hiperactiva
AR081439A1 (es) Composicion para el tratamiento de la hiperplasia prostatica benigna de prostata
BR0014166A (pt) Método de utilização de inibidores de reabsorção de serotonina seletivo de rápido ataque para tratamento de disfunção sexual
CL2022003039A1 (es) Inhibidores de il4i1 y métodos de uso.
AR015744A1 (es) Uso de dexmedetomidina para sedacion en terapia intensiva
RU2007138263A (ru) Противовоспалительные соединения
ES2124983T3 (es) Utilizacion de un antagonista de substancia p para el tratamiento de las manchas rojas cutaneas de origen neurogeno.
BRPI0517953A (pt) uso de zd 6474, ou de um sal farmaceuticamente aceitável do mesmo, e de um antiandrógeno, composição farmacêutica, kit, e, método para a produção de um efeito da redução da permeabilidade vascular e/ou antiangiogênico em um animal de sangue quente
CO6190520A2 (es) Metodos para el tratamiento del abuso adiccion y dependencia del alcohol
UY26648A1 (es) Inhibidores de vasopeptidasa para tratar hipertensión sistólica aislada

Legal Events

Date Code Title Description
FA Application withdrawn